BCRX Logo

BioCryst Pharmaceuticals, Inc. (BCRX) 

NASDAQ
Market Cap
$1.55B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
103 of 774
Rank in Industry
72 of 432

Largest Insider Buys in Sector

BCRX Stock Price History Chart

BCRX Stock Performance

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 …

Insider Activity of BioCryst Pharmaceuticals, Inc.

Over the last 12 months, insiders at BioCryst Pharmaceuticals, Inc. have bought $1.05M and sold $123,411 worth of BioCryst Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at BioCryst Pharmaceuticals, Inc. have bought $673,474 and sold $5.21M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Thackray Helen M. (Chief R&D Officer) — $351,600. Doyle Anthony (Chief Financial Officer) — $202,191. Stonehouse Jon P (President & CEO) — $166,500.

The last purchase of 7,861 shares for transaction amount of $49,996 was made by LEVIN ALAN G (director) on 2024‑05‑30.

List of Insider Buy and Sell Transactions, BioCryst Pharmaceuticals, Inc.

2024-06-24Saledirector
8,600
0.0042%
$6.32$54,352+22.33%
2024-06-17Saledirector
4,689
0.0021%
$6.00$28,134+22.36%
2024-06-14Saledirector
6,698
0.0031%
$6.11$40,925+23.66%
2024-05-30Purchasedirector
7,861
0.0037%
$6.36$49,996+15.30%
2024-05-24Purchasedirector
2,500
0.0012%
$6.40$16,000+23.16%
2024-05-20Purchasedirector
5,000
0.0025%
$6.38$31,900+22.88%
2024-05-20Purchasedirector
15,000
0.0074%
$6.25$93,750+22.88%
2024-05-14PurchaseChief R&D Officer
30,000
0.0159%
$5.86$175,800+40.00%
2024-05-14PurchaseChief Financial Officer
36,300
0.0183%
$5.57$202,191+40.00%
2024-05-13PurchasePresident & CEO
30,000
0.0143%
$5.55$166,500+32.71%
2024-05-13PurchaseChief Commercial Officer
30,000
0.0141%
$5.47$164,100+32.71%
2024-05-13PurchaseChief Legal Officer
5,000
0.0024%
$5.53$27,650+32.71%
2024-05-13Purchasedirector
21,940
0.0104%
$5.49$120,451+32.71%
2023-06-15Saledirector
4,000
0.0021%
$7.98$31,920-24.59%
2023-06-14Saledirector
12,866
0.0069%
$8.04$103,443-24.06%
2023-04-03SaleChief R&D Officer
7,000
0.0037%
$8.29$58,030-19.09%
2023-02-01SalePresident & CEO
100,000
0.0523%
$10.38$1.04M-31.89%
2022-12-15SalePresident & CEO
14,100
0.0079%
$10.90$153,690-30.48%
2022-12-15SaleChief Commercial Officer
6,100
0.0034%
$10.90$66,490-30.48%
2022-12-15SaleChief Legal Officer
4,175
0.0023%
$10.88$45,424-30.48%

Insider Historical Profitability

103.06%
Stonehouse Jon PPresident & CEO
1127770
0.5445%
$7.49148+33.26%
Gayer Charles KChief Commercial Officer
307533
0.1485%
$7.4911
Barnes Alane PChief Legal Officer
300762
0.1452%
$7.4928+118.24%
Thackray Helen M.Chief R&D Officer
272139
0.1314%
$7.4913
Doyle AnthonyChief Financial Officer
266744
0.1288%
$7.4931+77.54%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$93.68M8.9418.44M-1.29%-$1.22M<0.01
The Vanguard Group$89.8M8.5717.68M-0.49%-$441,721.24<0.01
State Street$88.78M8.4717.48M+36.79%+$23.88M<0.01
Avoro Capital Advisors Llc$66.29M6.3213.05M0%+$00.79
Baker Bros Advisors LP$51.44M4.9110.13M0%+$00.37
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.